Jane Street’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-62,900
| Closed | -$326K | – | 10900 |
|
|
2024
Q3 | $326K | Buy |
+62,900
| New | +$313K | ﹤0.01% | 7888 |
|
|
2024
Q1 | – | Sell |
-154,100
| Closed | -$1.35M | – | 10274 |
|
|
2023
Q4 | $1.35M | Sell |
154,100
-84,600
| -35% | -$693K | ﹤0.01% | 5018 |
|
|
2023
Q3 | $2.74M | Sell |
238,700
-41,100
| -15% | -$790K | ﹤0.01% | 3517 |
|
|
2023
Q2 | $7.08M | Buy |
279,800
+73,000
| +35% | +$2.27M | ﹤0.01% | 2292 |
|
|
2023
Q1 | $6.66M | Sell |
206,800
-480,900
| -70% | -$15M | ﹤0.01% | 2083 |
|
|
2022
Q4 | $12.7M | Sell |
687,700
-15,300
| -2% | -$350K | 0.01% | 1380 |
|
|
2022
Q3 | $19M | Buy |
703,000
+609,100
| +649% | +$12.4M | 0.01% | 1111 |
|
|
2022
Q2 | $1.3M | Sell |
93,900
-21,300
| -18% | -$328K | ﹤0.01% | 4997 |
|
|
2022
Q1 | $2.25M | Buy |
115,200
+35,800
| +45% | +$543K | ﹤0.01% | 4531 |
|
|
2021
Q4 | $1.3M | Buy |
79,400
+60,400
| +318% | +$1.01M | ﹤0.01% | 5390 |
|
|
2021
Q3 | $529K | Sell |
19,000
-51,200
| -73% | -$1.46M | ﹤0.01% | 7178 |
|
|
2021
Q2 | $2.08M | Sell |
70,200
-29,400
| -30% | -$848K | ﹤0.01% | 4261 |
|
|
2021
Q1 | $2.78M | Buy |
99,600
+73,300
| +279% | +$2.03M | ﹤0.01% | 3400 |
|
|
2020
Q4 | $745K | Buy |
26,300
+9,700
| +58% | +$251K | ﹤0.01% | 5136 |
|
|
2020
Q3 | $417K | Buy |
+16,600
| New | +$435K | ﹤0.01% | 5437 |
|
|
2016
Q1 | – | Sell |
-6,900
| Closed | -$236K | – | 4749 |
|
|
2015
Q4 | $236K | Buy |
+6,900
| New | +$239K | ﹤0.01% | 3389 |
|
Other funds holding RVNC
Jane Street's RVNC Position: Q1 2025 in Review
Jane Street sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 113,150 shares — an estimated $344K sold.
Jane Street first reported a position in RVNC in Q4 2017 and held it in 19 quarters. The position peaked at $8.85M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Jane Street reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Jane Street sold 113,150 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $344K.
- Jane Street first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 19 quarters.
- Jane Street's Revance Therapeutics, Inc. position peaked at $8.85M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.